112 related articles for article (PubMed ID: 17099875)
1. Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifies C9orf14 as a candidate tumor-suppressor.
Pujana MA; Ruiz A; Badenas C; Puig-Butille JA; Nadal M; Stark M; Gómez L; Valls J; Solé X; Hernández P; Cerrato C; Madrigal I; de Cid R; Aguilar H; Capellá G; Cal S; James MR; Walker GJ; Malvehy J; Milà M; Hayward NK; Estivill X; Puig S
Genes Chromosomes Cancer; 2007 Feb; 46(2):155-62. PubMed ID: 17099875
[TBL] [Abstract][Full Text] [Related]
2. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization.
Rákosy Z; Vízkeleti L; Ecsedi S; Bégány A; Emri G; Adány R; Balázs M
Cancer Genet Cytogenet; 2008 Apr; 182(2):116-21. PubMed ID: 18406873
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort.
Falchi M; Spector TD; Perks U; Kato BS; Bataille V
Hum Mol Genet; 2006 Oct; 15(20):2975-9. PubMed ID: 16928783
[TBL] [Abstract][Full Text] [Related]
4. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts).
Langezaal SM; Graadt van Roggen JF; Cleton-Jansen AM; Baelde JJ; Hogendoorn PC
Br J Cancer; 2001 Feb; 84(4):535-8. PubMed ID: 11207050
[TBL] [Abstract][Full Text] [Related]
5. Molecular cloning of the breakpoint region on chromosome 6 in cutaneous malignant melanoma: evidence for deletion in the c-myb locus and translocation of a segment of chromosome 12.
Dasgupta P; Linnenbach AJ; Giaccia AJ; Stamato TD; Reddy EP
Oncogene; 1989 Oct; 4(10):1201-5. PubMed ID: 2677917
[TBL] [Abstract][Full Text] [Related]
6. Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Jönsson G; Bendahl PO; Sandberg T; Kurbasic A; Staaf J; Sunde L; Crüger DG; Ingvar C; Olsson H; Borg A
J Natl Cancer Inst; 2005 Sep; 97(18):1377-82. PubMed ID: 16174859
[TBL] [Abstract][Full Text] [Related]
7. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
8. Molecular processes of chromosome 9p21 deletions in human cancers.
Sasaki S; Kitagawa Y; Sekido Y; Minna JD; Kuwano H; Yokota J; Kohno T
Oncogene; 2003 Jun; 22(24):3792-8. PubMed ID: 12802286
[TBL] [Abstract][Full Text] [Related]
9. A malignant melanoma tumor suppressor on human chromosome 11.
Robertson G; Coleman A; Lugo TG
Cancer Res; 1996 Oct; 56(19):4487-92. PubMed ID: 8813145
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21.
Fung JM; Smith R; Brown MA; Lau SH; Xie D; Lau GK; Guan XY
Clin Cancer Res; 2009 Feb; 15(3):797-803. PubMed ID: 19188149
[TBL] [Abstract][Full Text] [Related]
11. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.
Martin ES; Cesari R; Pentimalli F; Yoder K; Fishel R; Himelstein AL; Martin SE; Godwin AK; Negrini M; Croce CM
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11517-22. PubMed ID: 14504409
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma.
Sini MC; Manca A; Cossu A; Budroni M; Botti G; Ascierto PA; Cremona F; Muggiano A; D'Atri S; Casula M; Baldinu P; Palomba G; Lissia A; Tanda F; Palmieri G
Br J Dermatol; 2008 Feb; 158(2):243-50. PubMed ID: 18028495
[TBL] [Abstract][Full Text] [Related]
13. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
14. Use of microgenomic technology for analysis of alterations in DNA copy number and gene expression in malignant melanoma.
Trent JM; Bittner M; Zhang J; Wiltshire R; Ray M; Su Y; Gracia E; Meltzer P; De Risi J; Penland L; Brown P
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():33-40. PubMed ID: 9020934
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal localization of phospholipase A2 activating protein, an Ets2 target gene, to 9p21.
Beatty BG; Qi S; Pienkowska M; Herbrick JA; Scheidl T; Zhang ZM; Kola I; Scherer SW; Seth A
Genomics; 1999 Dec; 62(3):529-32. PubMed ID: 10644453
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous malignant melanoma and atypical moles associated with a constitutional rearrangement of chromosomes 5 and 9.
Petty EM; Bolognia JL; Bale AE; Yang-Feng T
Am J Med Genet; 1993 Jan; 45(1):77-80. PubMed ID: 8418665
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl PO; Ringnér M; Guldberg P; Borg A
Oncogene; 2007 Jul; 26(32):4738-48. PubMed ID: 17260012
[TBL] [Abstract][Full Text] [Related]
18. Molecular analyses of the candidate tumor suppressor gene, PLAGL1, in benign and malignant salivary gland tumors.
Enlund F; Persson F; Stenman G
Eur J Oral Sci; 2004 Dec; 112(6):545-7. PubMed ID: 15560839
[TBL] [Abstract][Full Text] [Related]
19. Genetic pathways to melanoma tumorigenesis.
Hussein MR
J Clin Pathol; 2004 Aug; 57(8):797-801. PubMed ID: 15280398
[TBL] [Abstract][Full Text] [Related]
20. Growth control by tumor suppressors in malignant melanoma.
Coleman A; Robertson G; Lugo TG
Receptor; 1995; 5(1):9-19. PubMed ID: 7613487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
